Cipla Limited (CIPLA)
Please find attached press release for Q1FY27 financial results
Press Release - Q1FY27
- Revenue 7,119 Cr +2% y-y; EBITDA 1,192 Cr (margin 16.7%, -890 bps y-y); PAT 789 Cr
- One India business grew 12% YoY with chronic mix at 60.4%
- North America revenue $162 Mn; launched gVentolin, Nintedanib, Dapagliflozin
- One Africa prescription business ranked No. 2; South Africa private market grew 6.5%
- Emerging Markets and Europe revenue grew 5% YoY in USD terms; sustained margins
- R&D spend at 486 Cr (6.8% of sales), up 12.3% YoY
- Net cash position strong at 9,494 Cr; debt mainly lease and working capital
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 CIPLA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add CIPLA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Cipla Limited
Important.
The summary above is generated automatically from Cipla Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.